Bacampicillin in acute exacerbations of chronic bronchitis—a dose-range study

Maesen, F. P. V.; Beeuwkes, H.; Davies, B. I.; Buytendijk, H J; Brombacher, P. J.; Wessman, J.

doi:10.1093/jac/2.3.279

Cited by 44 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a more systematic study Maesen et al. (10) reported fully satisfactory concentrations in the sputum of patients with chronic bronchitis treated with bacampicillin, 400 or 800 mg. In the cases in which beta-streptococci were isolated initially, these microorganisms disappeared during the course of treatment.…”

Section: Resultsmentioning

confidence: 98%

Pharmacological and Clinical Study of Bacampicillin in Acute Peritonsillitis–a Comparison with Ampicillin

Hallander¹,

Flodström²,

Sjövall³

1977

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The pharmacological and clinical properties of bacampicillin in three dosage groups were studied in 66 hospitalized patients with unilateral acute peritonsillitis in a comparison with ampicillin. Bacampicillin is a new semisynthetic aminopenicillin which is rapidly converted to ampicillin but is better absorbed. Both drugs were given orally. The mean individual peak serum levels achieved with 200, 400, and 800 mg of bacampicillin in the first morning dose were 4.9, 6.8, and 11.9 mg/liter, respectively, with an almost linear dose response. The peak level of 800 mg of bacampicillin was significantly higher than the 6.8 mg/liter noted after a nearly equimolar dose of 500 mg of ampicillin. A linear relationship was also seen between dose and area under the serum concentration-time curve. Preliminary antibiotic concentration studies in five patients indicated therapeutic levels in peritonsillar pus. Beta-streptococci alone or in combination with anaerobes were isolated from about half ofthe abscesses, whereas anaerobes were isolated from the other half. Treatment was supplemented by surgical procedures in the majority of cases. The clinical effect was good in all treatment groups, with only one relapse. All beta-streptococci were eliminated during therapy. The total number ofgastrointestinal side effects was significantly lower in patients treated with bacampicillin, although the difference in frequency of diarrhea alone was not significant.

show abstract

Section: Resultsmentioning

confidence: 98%

Pharmacological and Clinical Study of Bacampicillin in Acute Peritonsillitis–a Comparison with Ampicillin

Hallander¹,

Flodström²,

Sjövall³

1977

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…These data will be reported in detail separately, but they show that concentrations in AMs are six to eight times those in ELF, which corresponds to the intracellular to extracellular concentration ratio observed in vitro (20). (14,20,28,33,36,39,50). It has been suggested that the concentrations at sites of infection may fall sufficiently to allow relapse of infection, because of reestablishment of normal barriers to movement (45).…”

Section: Introductionmentioning

confidence: 85%

“…First, there are problems with defining end points in respiratory infections. Resolution of a chest infection may be indicated by normalization of the body temperature, clearing of purulent sputum, time for bacterial eradication from sputum, and absence of reinfection during a follow-up period (13,19,33,40). All of these measures do not necessarily equate with clinical response.…”

Section: Introductionmentioning

confidence: 99%

Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance

Baldwin

Honeybourne

Wise

1992

Antimicrob Agents Chemother

111

View full text Add to dashboard Cite

“…Maesen et al (1976), treated acute exacerbations of chronic bronchitis with increasing doses of bacampicillin: in their 12-8 ± 1-4 20 ±0-4 14-9 ± 19 study, the clinical and microbiological success of the treatment was related to the levels of ampicillin in the bronchial secretions. In a group of patients with acute bronchitis or pneumonia treated with amoxycillin, Stewart et al (1974) showed a more favourable clinical outcome in the patients with a high sputum level of the drug than those with a low one.…”

Section: Discussionmentioning

confidence: 99%

“…With respect to the optimal antibiotic regimen for bronchopulmonary infections, it has been suggested that the concentrations of the antibiotic in bronchial secretions might be of critical importance in the therapeutic outcome of these infections 29 0305-7453/81 /8C0029*O8 JO 1.00/0 © 1981 The British Society for Antimicrobial Chemotherapy (Stewart et al, 1974;Maesen et al, 1976;Klastersky et al, 1979). The bioactive levels of aminoglycosides in bronchial secretions after systemic administration are relatively low when compared to the minimum inhibitory concentration of most Gram-negative bacilli.…”

Section: Introductionmentioning

confidence: 99%

Peak or sustained antibiotic serum levels for optimal tissue penetration

Thys

Klastersky

Mombelli

1981

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

A comparative study of the levels of netilmicin in bronchial secretions after intermittent and during continuous intravenous injections was performed. During the first 2 h, the areas under the drug concentration curves in the bolus injection experiment were greater in serum and in bronchial secretions (206 and 150% respectively) than those associated with the continuous infusion (P<0 i 001); however, during the 8 h experimental period, the areas under the curves were similar in serum and bronchial secretions with the two modes of administration. The percentages of penetration of netilmicin from the blood to the bronchial lumen were also similar with the two modes of administration (19%). After intramuscular administration of amikacin (75 and 125 mg/kg twice daily), the peak bronchial secretion levels of the drug were 44 and 10-1 mg/1 respectively and the trough levels about 1 mg/1. During continuous iv injection of amikacin (7-12 mg/kg/8 h), the drug level in the bronchial secretions was only 20 mg/1 and the percentage of penetration was 14*9%; adequate anXi-Pseudomonas activity in bronchial secretions was rarely achieved. It is therefore suggested that intermittent injections of aminoglycosides can result in at least transitory higher bronchial secretion levels than continuous injection: the intermittent schedule of antibiotic administration could therefore be recommended in the treatment of bronchopulmonary infections since it has been suggested that the concentration of antibiotic in bronchial secretions could be important in the outcome of these infections.

show abstract

Bacampicillin in acute exacerbations of chronic bronchitis—a dose-range study

Cited by 44 publications

References 0 publications

Pharmacological and Clinical Study of Bacampicillin in Acute Peritonsillitis–a Comparison with Ampicillin

Pharmacological and Clinical Study of Bacampicillin in Acute Peritonsillitis–a Comparison with Ampicillin

Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance

Peak or sustained antibiotic serum levels for optimal tissue penetration

Contact Info

Product

Resources

About